Stock AMPH AMPHASTAR PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Market Closed - Nasdaq
Other stock markets
 01:30:00 18/06/2024 am IST 		5-day change 1st Jan Change
40.54 USD +0.12% Intraday chart for Amphastar Pharmaceuticals, Inc. -2.64% -34.45%
04/06 Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director CI
04/06 Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director
CI
Amphastar Pharmaceuticals' Board Approves $50 Million Increase to Share Buyback Plan
MT
Amphastar Pharmaceuticals, Inc. announces an Increase in Equity Buyback.
CI
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
AQ
Sector Update: Health Care Stocks Slightly Higher Late Afternoon
MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon
MT
Amphastar Pharmaceuticals Gains US FDA Approval for Generic Bronchospasm Drug
MT
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
CI
Transcript : Amphastar Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM
Tranche Update on Amphastar Pharmaceuticals, Inc.'s Equity Buyback Plan announced on November 8, 2016.
CI
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
AQ
Transcript : Amphastar Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024
Amphastar: Q1 Earnings Snapshot
AQ
Amphastar Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 EPS $1.04, vs. Street Est of $0.79
MT
Earnings Flash (AMPH) AMPHASTAR PHARMACEUTICALS Reports Q1 Revenue $171.8M, vs. Street Est of $174.7M
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. News Amphastar Pharmaceuticals, Inc.